140 related articles for article (PubMed ID: 29058958)
1. Biomarkers in mesothelioma.
Arnold DT; Maskell NA
Ann Clin Biochem; 2018 Jan; 55(1):49-58. PubMed ID: 29058958
[TBL] [Abstract][Full Text] [Related]
2. Serum and pleural fluid biomarkers for mesothelioma.
Creaney J; Robinson BW
Curr Opin Pulm Med; 2009 Jul; 15(4):366-70. PubMed ID: 19417672
[TBL] [Abstract][Full Text] [Related]
3. Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment.
Creaney J; Robinson BWS
Chest; 2017 Jul; 152(1):143-149. PubMed ID: 28007619
[TBL] [Abstract][Full Text] [Related]
4. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW
J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
[TBL] [Abstract][Full Text] [Related]
5. Prognostication and monitoring of mesothelioma using biomarkers: a systematic review.
Arnold DT; De Fonseka D; Hamilton FW; Rahman NM; Maskell NA
Br J Cancer; 2017 Mar; 116(6):731-741. PubMed ID: 28170372
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
Bruno F; Baratti D; Martinetti A; Morelli D; Sottotetti E; Bonini C; Guaglio M; Kusamura S; Deraco M
Eur J Surg Oncol; 2018 Jun; 44(6):792-798. PubMed ID: 29503128
[TBL] [Abstract][Full Text] [Related]
7. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
Creaney J; Yeoman D; Musk AW; de Klerk N; Skates SJ; Robinson BW
Lung Cancer; 2011 Oct; 74(1):55-60. PubMed ID: 21397972
[TBL] [Abstract][Full Text] [Related]
8. Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma.
Creaney J; Dick IM; Robinson BW
Curr Opin Pulm Med; 2015 Jul; 21(4):352-6. PubMed ID: 26016578
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers for malignant pleural mesothelioma: current status.
Greillier L; Baas P; Welch JJ; Hasan B; Passioukov A
Mol Diagn Ther; 2008; 12(6):375-90. PubMed ID: 19035624
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.
Pantazopoulos I; Boura P; Xanthos T; Syrigos K
Eur Respir J; 2013 Mar; 41(3):706-15. PubMed ID: 22835614
[TBL] [Abstract][Full Text] [Related]
11. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
12. Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers.
Sorino C; Mondoni M; Marchetti G; Agati S; Inchingolo R; Mei F; Flamini S; Lococo F; Feller-Kopman D
J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002620
[TBL] [Abstract][Full Text] [Related]
13. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
Creaney J; van Bruggen I; Hof M; Segal A; Musk AW; de Klerk N; Horick N; Skates SJ; Robinson BW
Chest; 2007 Oct; 132(4):1239-46. PubMed ID: 17646232
[TBL] [Abstract][Full Text] [Related]
14. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
Hollevoet K; Nackaerts K; Gosselin R; De Wever W; Bosquée L; De Vuyst P; Germonpré P; Kellen E; Legrand C; Kishi Y; Delanghe JR; van Meerbeeck JP
J Thorac Oncol; 2011 Nov; 6(11):1930-7. PubMed ID: 21841505
[TBL] [Abstract][Full Text] [Related]
15. Current status of screening for malignant pleural mesothelioma.
Pass HI; Carbone M
Semin Thorac Cardiovasc Surg; 2009; 21(2):97-104. PubMed ID: 19822280
[TBL] [Abstract][Full Text] [Related]
16. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.
Creaney J; Olsen NJ; Brims F; Dick IM; Musk AW; de Klerk NH; Skates SJ; Robinson BW
Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2238-46. PubMed ID: 20651076
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for mesothelioma.
Scherpereel A; Lee YC
Curr Opin Pulm Med; 2007 Jul; 13(4):339-443. PubMed ID: 17534183
[TBL] [Abstract][Full Text] [Related]
18. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels.
Rai AJ; Flores RM; Mathew A; Gonzalez-Espinoza R; Bott M; Ladanyi M; Rusch V; Fleisher M
Clin Chem Lab Med; 2010 Feb; 48(2):271-8. PubMed ID: 20131968
[TBL] [Abstract][Full Text] [Related]
19. Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.
Creaney J; Segal A; Olsen N; Dick IM; Musk AW; Skates SJ; Robinson BW
Dis Markers; 2014; 2014():413946. PubMed ID: 25505814
[TBL] [Abstract][Full Text] [Related]
20. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P
Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]